Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 10—October 2016

Resolution of a Chikungunya Outbreak in a Prospective Cohort, Cebu, Philippines, 2012–2014

Anon SrikiatkhachornComments to Author , Maria Theresa Alera, Catherine B. Lago, Ilya A. Tac-An, Daisy Villa, Stefan Fernandez, Butsaya Thaisomboonsuk, Chonticha Klungthong, Jens W. Levy, John Mark Velasco, Vito G. Roque, Ananda Nisalak, Louis R. Macareo, and In-Kyu Yoon1
Author affiliations: University of Rhode Island, Providence, Rhode Island, USA (A. Srikiatkhachorn); Armed Forces Research Institute of Medical Sciences Virology Research Unit, Cebu City, Philippines (M.T. Alera, C.B. Lago); Cebu City Health Department, Cebu City (I.A. Tac-An, D. Villa); Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand (S. Fernandez, B. Thaisomboonsuk, C. Klungthong, J.W. Levy, J.M. Velasco, A. Nisalak, L.R. Macareo, I.K. Yoon); Philippines Department of Health National Epidemiology Center, Manila, Philippines (V.K. Roque, Jr.)

Main Article


Incidence of subclinical and symptomatic chikungunya virus infection during 2 years of active surveillance in an age-stratified cohort, Cebu, Philippines, 2012–2014*

Only persons with negative neutralizing antibodies at beginning of 2nd year, by age
6 mo–5 y 2/1.84 (0.37–5.89) 1/0.92 (0.08–4.28) 3/2.76 (0.76–7.35)
6–15 y 1/0.77 (0.07–3.6) 3/2.32 (0.64–6.18) 4/3.09 (1.03–7.35)
16–30 y 1/1.15 (0.1–5.36) 4/4.6 (1.54–10.94) 5/5.75 (2.18–12.6)
31–50 y 1/2.11 (0.19–9.82) 4/8.43 (2.82–20.03) 5/10.53 (3.99–23.09)
>50 y 1/2.05 (0.19–9.55) 3/6.15 (1.7–16.4) 4/8.2 (2.74–19.49)
All ages 6/1.42 (0.59–2.93) 15/3.56 (2.08–5.72) 21/4.98 (3.18–7.47)

Bold indicates significantly different (p<0.05) from incidence observed among the corresponding age groups during the first year of surveillance. Prevalence of neutralizing antibodies at the beginning of the first year was 28% and at the beginning of the second year was 42%.

Main Article

1Current affiliation: International Vaccine Institute, Seoul, South Korea.

Page created: September 20, 2016
Page updated: September 20, 2016
Page reviewed: September 20, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.